Gilbert Cisneros Buys Shares of Vaxcyte, Inc. (PCVX)

U.S. Rep. Gilbert Cisneros disclosed a purchase of Vaxcyte shares valued between $1,001 and $15,000.

Written by Trueearnings · Published Jun 13, 2026, 2:10 AM EDT · Updated Jun 14, 2026, 8:01 PM EDT

Key Points

U.S. Representative Gilbert Cisneros bought Vaxcyte shares valued between $1,001 and $15,000, as disclosed on June 9, 2026.
Vaxcyte, Inc. trades on NasdaqGS under the ticker PCVX, with a market cap of $6.85 billion and a 52-week range between $29.08 and $65.00.
Major institutional holders like Janus Henderson and BlackRock have also adjusted their positions in Vaxcyte recently.

Congressional trading track record

Gilbert Cisneros vs. the S&P 500

YTD return -1.4% hypothetical

All-time return -1.0% S&P 500 +93.0%

vs. S&P 500 -94.0% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

On June 9, 2026, U.S. Representative Gilbert Cisneros disclosed a purchase of Vaxcyte, Inc. shares on NasdaqGS under the ticker PCVX. The transaction, which took place on May 13, 2026, was valued between $1,001 and $15,000. This disclosure comes as part of the STOCK Act requirements for Congressional members.

Other Institutional Activity in Vaxcyte

Several institutional investors have been active in Vaxcyte, Inc. Janus Henderson Group PLC increased its holdings by 3,188,687 shares, bringing its total to 16,575,875 shares valued at approximately $960.2 million. FMR LLC also boosted its position by 2,658,347 shares, ending with 16,492,861 shares worth about $958.4 million. T. Rowe Price Investment Management, Inc. added 829,684 shares, resulting in a total of 12,126,017 shares valued at $704.6 million. RA Capital Management, L.P. and BlackRock, Inc. both made smaller additions of 750,000 and 725,438 shares, respectively.

Vaxcyte Stock Snapshot

Shares of Vaxcyte, Inc. (NasdaqGS: PCVX) traded near $47.46. The company has a market cap of approximately $6.85 billion. Vaxcyte is not currently profitable, so it doesn't have a meaningful P/E ratio. The stock's 52-week range is between $29.08 and $65.00, with a 50-day moving average of $54.48 and a 200-day moving average of $48.67. The company's beta is 1.242, indicating moderate volatility compared to the broader market.

Insider Buying and Selling at Vaxcyte, Inc.

Recent insider activity at Vaxcyte includes several planned sales by Chief Operating Officer Jim Wassil, who sold 2,250 shares at prices ranging from $49.52 to $58.43 between April and June 2026. Additionally, Elvia Cowan, SVP of Finance & CAO, sold 3,000 shares at $60.00 on April 7, 2026, in a planned transaction.

Analysts Set New Price Targets

On February 26, 2026, BTIG maintained its buy rating on Vaxcyte with a price target of $89.00. Earlier, on February 2, 2026, Guggenheim reiterated its buy rating with a target of $116.00. Needham also maintained a buy rating on January 7, 2026, setting a target of $110.00. Analysts' consensus reflects a strong buy recommendation with an average target price of $109.00.

About Vaxcyte, Inc.

Vaxcyte, Inc. is a biotechnology company based in San Carlos, California. The company is focused on developing vaccines to prevent or treat bacterial infectious diseases. Its lead product, VAX-24, is designed to prevent invasive pneumococcal disease in infants. Vaxcyte also has several other vaccine candidates in various stages of development. The company, led by CEO Grant E. Pickering, employs around 507 people.

Bottom Line

The purchase by Gilbert Cisneros highlights ongoing interest in Vaxcyte, Inc., a company actively engaged in vaccine development. While 13F filings and Congressional disclosures are backward-looking, they offer insights into investment trends and institutional confidence. Investors often track these moves to gauge market sentiment, but it's important to remember these filings may not reflect the most current positions.